The role that G-protein coupled receptors (GPCRs) play in modern pharmacology is not just diverse and vital, but also ever-evolving. As a significant element in cell communication, GPCRs have been the target for drug discovery and development. While compounds targeting GPCRs have been largely developed to treat pain, inflammation, and several neurobiological and other disorders, they are also used in food and cosmetics segments to modulate taste and smell.
A report published by Transparency Market Research studies the way G-protein coupled receptors are changing the face of drug discovery.
Innovative and Advanced Applications of GPCRs Paving Way for Growth
GPCRs are the target of an estimated 30% drugs in the market today. Associate Professor Kevin Pfleger at the Harry Perkins Institute of Medical Research, along with his colleagues, recently found that a bioluminescent protein found in deep sea shrimp can prove to be a game-changer in monitoring the manner in which drugs interact with live cells.
Browse The Market Research Report of G-Protein Coupled Receptors (GPCRs) Market:
The team used bioluminescence resonance energy transfer (BRET) along with NanoLuc combined with GPCRs to observe how drugs or natural hormones bind to cell surface receptors. Dr Pfleger said that drug discovery researchers working on other drug targets could also benefit from using the BRET principle and NanoLuc.
Drug discovery and development activities such as these are one of the major factors contributing to the growth of the G-protein coupled receptors market. Other factors that drive the GPCRs market include growing demand for advanced GPCR assays and assay systems, increasing incidence of respiratory, cardiovascular, neurological, and reproductive disorders, and rise in government initiatives and collaborations. However, high cost of instruments and equipment and costly maintenance of cell lines threaten to inhibit the growth of the G-protein coupled receptors market.
North America Emerges as the Most Advanced Market for GPCRs
The companies operating in the global market for G-protein coupled receptors have made innovation their main focus in order to develop technologically advanced GPCR assays and platforms and thereby gain a competitive edge over the others. Enzo Life Sciences, Inc., Promega Corporation, PerkinElmer, Inc., Qiagen N.V., EMD (Merck) Millipore, Thermo Fisher Scientific, Inc., Cisbio Bioassays, HD Biosciences Co. Ltd., Abcam plc, Sigma-Aldrich Corporation, DiscoveRx Corporation, and Becton, Dickinson and Company are some of the leading players in the GPCRs market. Of these, EMD Millipore, Thermo Fisher Scientific, PerkinElmer, Becton, Dickinson and Company, and Sigma-Aldrich are known to be functioning in most GPCR segments.
High awareness about advanced assays, growing demand for innovative and technologically advanced products in hospitals, financial capacity to purchase high-end machinery and equipment, and greater investments in healthcare research and development has rendered North America the largest market for G-protein coupled receptors in the world. The global GPCRs market, according to TMR, is projected to reach US$3,533.4 million by 2022, developing at a healthy CAGR of 8.8% from 2014 to 2022.
Browse The Press Release of G-Protein Coupled Receptors (GPCRs) Market:
The field of G-protein coupled receptors still presents a world of untapped opportunities and increased research and development activities are sure to prove beneficial for new and emerging players in the market.
No comments:
Post a Comment